A study to Evaluate a Potassium Normalization Treatment Regimen Including Sodium Zirconium Cyclosilicate (ZS) among patients with S-K ≥5.8 - ENERGIZE

Study identifier:D9480C00005

ClinicalTrials.gov identifier:NCT03337477

EudraCT identifier:2017-003955-50

CTIS identifier:N/A

Study Complete

Official Title

A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate a Potassium Normalization Treatment Regimen Including Sodium Zirconium Cyclosilicate (ENERGIZE)

Medical condition

Hyperkalemia

Phase

Phase 2

Healthy volunteers

No

Study drug

Placebo, Sodium Zirconium Cyclosilicate(ZS), Insulin, Glucose

Sex

All

Actual Enrollment

70

Study type

Interventional

Age

18 Years - 130 Years

Date

Study Start Date: 13 Feb 2018
Primary Completion Date: 21 Dec 2018
Study Completion Date: 21 Dec 2018

Study design

Allocation: Randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment

Verification:

Verified 01 Jan 2020 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria